The latest update is out from ImmunityBio (IBRX).
ImmunityBio, Inc. has approved significant discretionary cash bonuses for its key executive officers, with payments scheduled for mid-March 2024. Additionally, the company has outlined the framework for its 2024 Long-Term Incentive Program, granting stock options and restricted stock units to these executives. These stock-based awards are set to vest over three years, incentivizing the long-term commitment of these top executives. Furthermore, the company has set new annual salary rates and target bonuses for the executives, effective from early March 2024, aligning their compensation with the company’s performance objectives.
Learn more about IBRX stock on TipRanks’ Stock Analysis page.
